Eli Lilly and Company (NYSE:LLY) Price Target Cut to $1,058.00 by Analysts at Leerink Partners

Eli Lilly and Company (NYSE:LLY) had its price objective decreased by Leerink Partners from $1,296.00 to $1,058.00 in a research note issued to investors on Monday morning,MarketScreener reports. Leerink Partners currently has an outperform rating on the stock.

LLY has been the subject of a number of other research reports. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 6th. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price objective for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Eli Lilly and Company in a research report on Friday, March 27th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,216.52.

Eli Lilly and Company Stock Down 1.7%

Shares of LLY opened at $868.59 on Monday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company’s fifty day moving average is $955.40 and its two-hundred day moving average is $985.96. The firm has a market cap of $820.66 billion, a PE ratio of 37.85, a price-to-earnings-growth ratio of 1.05 and a beta of 0.51. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently modified their holdings of the stock. Appalachian Capital Management Ltd boosted its stake in shares of Eli Lilly and Company by 6.8% in the first quarter. Appalachian Capital Management Ltd now owns 363 shares of the company’s stock valued at $334,000 after purchasing an additional 23 shares during the period. HB Wealth Management LLC increased its stake in Eli Lilly and Company by 6.6% during the 1st quarter. HB Wealth Management LLC now owns 63,028 shares of the company’s stock worth $57,972,000 after buying an additional 3,907 shares during the period. Moran Wealth Management LLC increased its stake in Eli Lilly and Company by 6.1% during the 1st quarter. Moran Wealth Management LLC now owns 11,265 shares of the company’s stock worth $10,361,000 after buying an additional 652 shares during the period. Counterpoint Mutual Funds LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth $4,786,000. Finally, Plimoth Trust Co. LLC boosted its position in Eli Lilly and Company by 5.0% in the 1st quarter. Plimoth Trust Co. LLC now owns 8,879 shares of the company’s stock valued at $8,167,000 after buying an additional 422 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion, adding AJ1-11095, a first‑in‑class Type II JAK2 inhibitor for myelofibrosis and polycythemia vera; the deal bolsters Lilly’s blood‑cancer pipeline and comes with Phase 1 data milestones later in 2026. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion (Reuters)
• Positive Sentiment: April marks a continued buying spree for Lilly—this is at least the second oncology acquisition this month—signaling management’s deliberate push to diversify beyond GLP‑1s and build durable oncology revenues. Lilly Bets Again on Blood Cancer With Second Acquisition This Month (Yahoo)
• Neutral Sentiment: Jim Cramer flagged Lilly as a company that “will tell a good story” heading into earnings despite recent controversy, reflecting that broadcasters and some investors expect management to present positive near‑term messaging. Jim Cramer Says Eli Lilly “Will Tell a Good Story When It Reports” (Yahoo)
• Neutral Sentiment: Analysts and preview pieces highlight that Q1 earnings will be pivotal: GLP‑1 demand, pricing pressure, and Foundayo launch trends are key metrics to watch when Lilly reports. Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts? (Zacks)
• Neutral Sentiment: Broader sector M&A (e.g., Organon/Sun Pharma) is keeping investor focus on consolidation in pharma, which can support valuation multiples for active acquirers like Lilly. Organon Rides the Pharma M&A Wave With Sun Takeover (Yahoo)
• Negative Sentiment: Prescription data show Lilly’s oral Foundayo trailing Novo Nordisk’s Wegovy pill at a similar launch stage, raising concerns about market share, launch momentum and near‑term revenue upside for Lilly’s obesity franchise. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival (Proactive)
• Negative Sentiment: Leerink Partners cut its price target on LLY from $1,296 to $1,058 while maintaining an outperform rating, a signal that at least some analysts see more near‑term downside or muted upside versus prior expectations. Leerink Partners adjusts PT on Eli Lilly (MarketScreener)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.